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DR.JOSEPH A. COTRUVO (U.S. EPA): Ifthere is
any occupation that is more frustrating than that
ofenvironmental epidemiologist, it must be that
of a regulatory decision maker who must use
environmental epidemiology study results as the
basis for controversial decisions. Somehow the
results are never conclusive, but rather "sugges-
tive," yet the consequences ofa decision one way
or the other may be substantial. The problem is
how to convert several pieces of equivocal data
into regulatory policy. Not only the epidemiology
but also the toxicology often leads to the same
uncertainties that must be reasonably resolved.
If you have any doubts after listening to Dr.
Calabrese andDr. Cantor, letmesuggestthatyou
try going to the mayor of a small town in the
Midwest, explaining to him that his water has
excessive amounts of radium in it, and that he
shouldtry to reduce it. What do you tell him after
he says "I have lived here 60 years and I have
never seen anybody die ofbone cancer"? Or, con-
sider another mayor who has barium in his water
and try to respond to his Congressman when he
says "God put the barium in the water and no
Federal agency is going to tell us to take it out."
That's a direct quote!
So theproblems are great and the science is not
all that clear. Nevertheless, decisions are neces-
sary. We usuallydo not have the option ofwaiting
for the next "definitive" study. The three papers
in this session did an excellentjob ofpointing out
a number ofthe strengths, weaknesses and com-
plexities ofenvironmental epidemiology.
I would distinguish between the first and the
second two papers in that Dr. Enterline directly
addressed occupational epidemiology. For all its
problems, I think the situation is infinitely better
there. At least there is the possibility of dealing
with high doses, somewhat controlled popula-
tions, and perhaps there are greater opportuni-
ties to arrive at less equivocal conclusions. In the
general environmental area (as opposed to occu-
pational) all ofthe questions ofcontrolling popu-
lations, looking for effects that may be very sub-
tle, looking for exposures that may not be unique
in those populations, and trying to control for all
ofthe complicating variables generate a formida-
ble task. Also, I would distinguish between the
two sets ofpapers in the sense that the asbestos
issue is one thatisreasonably resolved. There is a
consensus that a cause-effect relationship be-
tween inhalation ofasbestos fibers and cancers of
various sorts indeed exists. The question at this
point is what is the standard to be, rather than if
there really is a problem. Generally, that is not
the situation in the environmental case. We are
still arguing over the existence or lack of exis-
tence of health effects that a standard would
purport to protect against in the general popula-
tion. So, the issue is much less clear.
Relative to Dr. Enterline's statements, he made
the very good point that we need to make some
judgments about the practicality of conducting
additional epidemiological studies in the area of
interest. One has to do some very careful plan-
ning to determine, first ofall, ifadditional epide-
miologicdata arenecessary. Secondly, can studies
in fact be designed that will lead to better under-
standing ofthe situation that exists? I would add,
are those studies essential in order to select the
final number for a standard? After all, once one
has concluded that a substance is actually a hu-
man carcinogen at common exposure levels, the
consensus, I believe, will argue for nonthreshold
mechanisms and thus the lowest practical expo-
sure. We are to a degree adding icing on the cake
by trying to refine justifications beyond that
point. Like it or not, the basic determinant in any
regulatory decision, and probably virtually every
decision everywhere, is economics, including
practicality and feasibility. And so, one goes a
certain distance with toxicology, a certain dis-
tance with epidemiology, and all of the other
technical factors in the analysis. But the bottom
line really is economics and what the public de-
mands.
I think both Dr. Calabrese and Dr. Cantor did
excellentjobs of pointing out all of the complex-
ities of collecting information and making deci-
sions from epidemiology in the environmental
area, but I would just make a statement on Dr.
Calabrese's concerns about quantitative risk as-
sessments in environmental decision-making,
andtheneedforconsistency. Ithinkall ofusmustDISCUSSION: SESSION IV
Table 1. Statistically significant results ofepidemiological cancer studies on drinking water and cancer sites.
Cancer sitesa
Liver Lung,
Intestine Combined and gall- Respiratory trachea, Uterus,
No. Author Yr. Oral Esophagus Stomach (not rectum) Rectum G.I. bladder Pancreas (not lung) bronchi Breast Cervix ovary
1 Page '74 - M
'76 F
2 Tarome '75- M - -
3b Vasilenko '75 F F - -
4 DeRousa '75 F M, F M -M - - F
5 Harris/Reiches '76- M M, F M M - - -
6 Buncher '75 M, F - - F F - F -
7 Kurma '77- M,F - F - F -
8c McCabe '75 -
9 Cantor '78 - -F - -M F
10 Hogan '79 -M -M -M, -F M,F F -M
11 Salg '77 M -F M M,F M - M F
12d Kruse '77-
13e Mah '77- -
14 Alvanja '77- M M M M M M
'78 F - - F -
15f Wilkins '78 - F
16 Rafferty '79
17g Brenniman '78 - F F F
18a luthill '78 M -F
18b uthill '79 M,F - -
l9h Struba '79- M, F
20i Gottlieb '80 - M, F
aE = ecological; C - C = case-control; F = positive association, females; M = positive association, males; -F = negative
association, females; -M = negative association, males.
bStudied females only.
cTItal cancer and total mortality only.
dStudied liver and kidney sites only.
eEight sites studied; no statistically positive association/geographic and data analysis problems.
fLiver, kidney and bladder only.
gCompleted but results not useable (females only).
hColon only.
iRectum and colon.
understand that this business ofrisk assessment
for chemicals in waterreallybegan seriously only
in 1978 or so, when the National Academy of
Science's Safe Drinking Water Committee pro-
duced its report. There were some isolated exam-
ples before then, but application of these risk
models to regulatory decisions is really a very
recent phenomenon. There is great controversy
and great amount of uncertainty, but I think
there really is a consensus in the Federal agen-
cies now, iffor no other reason than the benzene
case and the Supreme Court's ruling, that one
uses all of the information that is available and
adds caveats as necessary. The Supreme Court, in
recommending that quantitative assessments be
made, very clearly pointed out that despite great
uncertainties in those quantitative assessments,
nevertheless ifthat is the best that science has to
offer, let's use it. And I think that is the way we
all feel about it at EPA and the other agencies.
Inthe Office ofDrinkingWater, wedo quantita-
tive risk assessments. We do not necessarily use
them as the determinant ofa standard, but we do
usethem aspart ofan assessment ofthe impact of
the standard. Perhaps some day as they are re-
finedwewillbe able to use them in amore specific
and quantitative sense.
Dr. Cantor talked about a number of studies
that had been done, and I think his final concern
was that EPA had made insufficient use of the
epidemiology that was available at the time we
wrote our drinking water standards for chloro-
form. I think we used itto the extentwe could use
it on its own merits, and on the interpretation of
the National Academy ofScience's Safe Drinking
Water Committee. All of those studies were, in
fact, quite preliminary, and in fact there were
some conflicts amongthem. Table 1 shows a list of
20 or so studies conducted through the period of
time 1974-80. You can see there is not a great
amount ofconsistency amongthem. In the case of
bladder cancer there is a reasonable concentra-DISCUSSION: SESSION IV
Table 1. (Continued)
Cancer sitesa
Combined Non-Hodgkins All Study
No. Yr. Prostate Bladder Kidney urinary Lymphatic Leukemia lymphoma Hodgkins Thyroid Brain Larnyx cancer type
1 '74 M - M E
'76 - E
2 '75 - - M E
3b '75 - F E
4 '75 - M - _ _
5 '76 M - M - - M, F E
6 '75 M, F E
7 '77 M - M, F E
8c '75 - M, F E
9 '78 M M, F - M E
10 '79 - M, F - -M, -F E
11 '77 M F M, F M, F M E
12d '77 - - - C-C
13e E
14 '77 - M M - M C-C
'78 F F C-C
15f '78 M C-C
16 '79 - E
17g '78 F C-C
18a '78 - - E
18b '79 E
19h '79 - C-C
20i '80 - - C-C
tion ofpositive results, some male, some female,
some both, some not. For stomach cancer, about
halfare positive and halfnegative; not so many in
the case of gastrointestinal cancer. We have to
keep in mind that the studies were usually very
preliminary. They did not control for many major
factors, including smoking, in the vast majority of
cases. As Dr. Cantor said, they were not quantita-
tive, they were qualitative. We used them in that
sense. We wentto great lengths to discuss them in
the standards. We rested our case on the toxicol-
ogy, but stated that it was supported by the hy-
pothesis generated by the epidemiology, and in
fact, I will admit that the qualitative impetus for
actually issuing the regulation at that time cer-
tainly was affected greatly by the existence of
these studies. So they had a major impact on the
decision process, even though they weren't neces-
sarily used to produce the numbers.
In closing, I would say that the problems are
great in arriving atthese decisions from available
data, the science is complex and not clear in its
interpretation. Iwould add my voice to the chorus
I heard at this meeting, and also one that I
attended last week on disinfection and risks,
which is that obviously epidemiologists, toxicolo-
gists and clinicians really must get together.
There is a great need for the marriage of all of
those techniques, and to my mind future research
should concentrate on the types ofstudies that do
involve actual collection of physical, biological,
and clinical data, whenever that is possible. Ex-
amples are the study that Dr. Calabrese reported
on sodium, and also anumberofstudies thathave
been done on use of various disinfectants, like
chlorine dioxide, where blood chemistry parame-
ters and other data from the exposed human
population were studied. I don't think there is
really any competition between the toxicologists
and the epidemiologists.
DR. K. CANTOR (U.S. EPA): Indeed, the epide-
miologic data now in existence are certainly not
uniform. They show different things going on in
different populations. There is a remarkable near
uniformity ofresults coming out ofmany ofthese
studies, though each study taken by itself has
severe restrictions. We certainly would not want
to base regulations on any individual study, but
overall I think it is remarkable that in the five
case-control mortality studies, for example, each
ofwhich investigated from three to up to 10 or 12
different cancer sites, in each of those five cases
rectal cancer appeared to be associated with the
surrogate measure of drinking water quality. I
don't want to push these results too hard, but I
think the data are becoming stronger every day.
The other issue I want to impress upon you is
the great advantage that advances in methodol-
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ogy are going to provide. That is, by getting
personal histories over a lifetime, such as infor-
mation on cigarette smoking or potential occupa-
tional exposures, in the case of the colon and
rectal cancer studies such data will permit a
quantitative estimate controlling for these varia-
bles in relation to dietary factors. I don't think
the problems that have plagued these earlier
studies will be evident in future ones. I don't
know of many studies that have looked at am-
bient environmental exposures in an analytic
sense. If the kinds of risk ratios that we are
seeing, that is in the neighborhood of1.5 and 2, in
fact are true, and indicate a causal relationship,
we will be able to see them clearly in subsequent
epidemiologic studies, and I think after a few
years we will have something that is believable
and reliable.
DR. THOMAS A. BURKE (New JerseyDepartment
ofEnvironmentalProtection): First Iwould like to
make acomment aboutthe needforepidemiologic
studies in light ofthe New Jersey experience. We
have conducted statewide monitoringprograms of
our ground water and public drinking water sup-
plies, and almost without exception every sample
contains some level of a carcinogenic chemical.
About 20% ofour ground water supplies, many of
which we thought were relatively pristine, con-
tain over 10 ppb of one or more of the common
carcinogenic organic solvents. On a local level,
the biggest problem that I face every day is an-
swering questions from the public about the
safety of their water. I wish I could quote Dr.
Cotruvo on his statement that the bottom line is
economics, because the bottom line cannot be
economics when one is talking about human
health on such a large scale ofexposure.
In view ofthe deactivation ofa lot ofepidemio-
logic work being done at EPA, I would like to ask
thepanel and Dr. Cotruvo what kind ofassistance
or future programs can we look forward to from
the Federal Government, to answer questions
about the safety ofthese substances in the drink-
ing water, and to assist us in assessing their
relationship to human health?
DR. COTRUVO: I think you can assume that the
Federal Government will continue to do every-
thing that can be done to evaluate these risks, by
whatever means necessary-toxicology, epide-
miology or whatever. It may be that there will be
new mechanisms for doing that. Organization-
ally, it is not my department that handles that
aspect, but my understanding is that work will
continue, but it will be done in a different atmo-
sphere perhaps.
I wouldjust add one comment on the matter of
conducting studies in the communities that you
are talking about. I think history has shown that
the probability ofbeing able to detect effects un-
der those situations you describe is extremely
poor, even if effects are present. I think epide-
miology has great limitations in its sensitivity in
being able to identify relatively low risk situa-
tions, and that is a basic problem. The cry always
is: Let's do an epidemiologic study in this commu-
nity to see if50 ppb ofTCE is causingcancers, but
such studies won't answer that question.
DR. VILMA HUNT (U.S. EPA): Probably now is
the time for me to say specifically what the plans
are for epidemiology in the Environmental Pro-
tection Agency, as I see it. I think Dr. Cantor's
presentation very clearly shows the direction that
we must go in terms of an approach to ensuring
more sensitive epidemiologic methods in the fu-
ture. It is evident thatthe relationships totoxicol-
ogy that I commented on yesterday have to be
built into the planning.
The linchpin to better studies is the best expo-
sure dose information that we can bring to the
system, knowing that for some situations one can
only make estimates ofpast exposures. When we
refer to toxicology information, be it genetic toxi-
cology or bioassay procedures, we are using some
surrogate that is not anywhere near the epidemi-
ologic setting ofa human population in a certain
environment.
EPA right now has neither mandate nor re-
sources to help improve cancer registries, to help
improve vital statistics reporting, or to help im-
prove diagnostic criteria for morbidity and mor-
tality. These are the job of the Department of
Health and Human Services. EPA does have a
responsibility and the capacity and capability to
put resources into exposure assessment and qual-
ity assurance, thus population exposure data can
indeed be improved. The toxicology base, which
could be in terms of both genetic toxicology,
short-term in vitro tests, as well as in vivo short-
and long-term bioassays, will also be important
in defining a dose-response relationship. If we
look at human populations and their exposures,
we may well be considering what you might call
population toxicology. Biochemical endpoints
may be reflective of the exposure, in situations
where we still do not know what the chronic
disease endpoint may be.
Where do we put our dollars? In EPA, with the
small resources we have, we provide a very small
proportion ofthe total epidemiologic dollarsbeing
spent by the Federal Government right now.
Probably we will direct those resources into expo-
sure assessment, where we can control the qual-DISCUSSION: SESSION IV
have to be more extensively studied in HHS as
Dr. Cantor has been doing as an EPA representa-
tive at NCI.
I leave you with the message that EPA's cur-
rent direction in best using its scarce resources is
in that part ofepidemiology studies which is the
exposure assessment component, and not as
strongly in the health effects component. In the
future, EPA's exposure assessment data can be
useful, coupled with a health effects component
coordinated to make larger studies more practi-
cal, rather than us using relatively few dollars to
put into an epidemiology study that does not
necessarily have enough resources to provide
both adequate exposure assessment and health
effects evaluation.
DR. P. ENTERLINE (Univ. ofPittsburgh): I would
not like to see epidemiology move away from
human health endpoints and become too en-
thralled with exposure assessment. I was talking
with some people in the control technology sec-
tion ofNIOSH several months ago about a prob-
lem in health assessment. Their response was:
"We are not going to wait to count dead bodies."
That is an interesting statement. But in this
particular case they didn't know if there was a
health problem. They knew there was exposure to
something. My point is simply: Why don't we find
out if the exposure has any harmful effects? I
think sometimes we make excuses for not study-
ing health endpoints adequately. Some of the
excuses are that it is difficult, some are that it
takes a lot of money, and some are we already
know the answer, what's the point in looking any
further? I think it is a mistake not to look. I think
that may be why there are problems in setting
some ofthe standards.
DR. HUNTP It is always good to start defining a
position because thenthe areas that were notwell
clarified canbebrought out. I did notwish to infer
that exposure assessment studies would be done
in isolation. In fact, I would argue there is not
much point in using exposure assessment ifone is
not doing a health endpoint evaluation as well. I
thinkthe idea I amtryingtopoint outhere isthat
EPA has in the past done studies within the
limits ofthe financial resources it had. They have
been very useful in generating hypotheses and
allowing a field to move forward. The needs we
have right now are directed at a more ambitious
approach, such as Dr. Cantor presented.
So I am looking at this issue in terms of a
collaborative approach to larger and more com-
plex, studies. I do not see doing exposure assess-
ment for its own sake. There are two sides ofthe
equation, exposure assessment and study of
ity ofthe work and ensure similarly that it links
well to the health effect endpoints, which may
health effects.
As an administrative or organizational change,
there may well be a shakedown period to assure
that the appropriate kinds ofinteraction between
Federal agencies develop. But given that all the
Federal agencies are likely to be changed in the
next couple ofyears, we had better make sure we
know how we want to get epidemiology studies
done, when organizational rearrangements are
occurring.
DR. PETER INFANTE (OSHA): I have a question
for Dr. Calabrese. You mentioned during your
presentation that you testified as an expert wit-
ness for OSHA on the subject of an aromatic
amine, where there was evidence in experimental
animals, but no evidence in humans ofsome kind
ofadverse effect, orpotential for an adverse effect.
Subsequently I understood you to make a com-
ment that public health decisions should be based
on epidemiologic data. It is this latter comment
on which I am asking for some clarification. Were
you talking about substances that were not car-
cinogens, or were you including carcinogens in
that statement also? Were you talking about so-
dium or some other things?
DR. CALABRESE: I was referring to a much more
general approach, and in this particular case, I
really hadn't limited it to either noncarcinogenic
or carcinogenic outcomes. Clearly if one is to
make some type of statement with respect to
setting standards, it is important to get informa-
tion from whatever sources are available.
In terms of scientific certainty, both animal
experimentation and epidemiological research
complement one another in attempting to resolve
the scientific issue. The ethical issue, however,
strongly supports the use, implementation and
extrapolation ofanimal studies, in taking a major
role in ultimately establishing what may be a
permissible exposure before any particular sub-
stance gets approved for interstate commerce. So
I don't think there is a fundamental difference. I
certainly appreciate your position and I don't
think there is a conflict here.
DR. COTRUVO: Just a comment to reiterate what
Dr. Calabrese said. I think what he is saying is
that you use all ofthe data that you get, and the
best that you can get, which is what we do. In the
case of drinking water standards, the fluoride
standard is entirely based on epidemiology. It is
pretty old epidemiology and it is being repeated
now, but that is where it came from. Other stan-
dards were based on combinations ofdata.
For the future, there are areas where we can
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get a lot ofinformation from specific studies. For
example, in the case ofnitrates, we may be inves-
tigating populations that have nitrate levels in
their water, looking for methemoglobin levels in
theblood. We do nothave towait formethemoglo-
binemia to occur, but we can relate the exposure
and the physiological reaction to it. The same can
be done with lead. We can find lead levels inblood
associated with drinking water and decide when
the drinking water is a significant contributor.
All ofthe above are important. It is notjust one
kind ofstudy, either animal toxicology or human
epidemiology.
DR. CALABRESE: I think the position that I was
defending during that particular court case was
the need to utilize animal studies to set regula-
tions, and not to wait to perform epidemiologic
studies to prove in fact that the animal studies
were indeed right, that a substance is actually a
human carcinogen. Clearly you have to use ani-
mal studies to prevent that type ofsituation.
One other thing I would like to comment on. A
great emphasis on characterizing exposure levels
and relatingthese to health outcomes is appropri-
ate. For example, does the individual smoke and
use saccharin? But one thing we really are not
characterizing well is: What is the health status
ofthe individual? Health may be looked at as the
net result ofthe impact ofenvironmental stresses
plusthe inherent adaptive capacity ofthe individ-
ual. If one is studying in a detailed fashion, for
example, bladder cancer, it would make sense to
me that one would want to include dietary infor-
mation in a questionnaire. Bladder cancers are
related to transformation ofepithelial tissue and
the integrity of epithelial tissue may be depen-
dentupon vitamin A status ofthe individual. And
if individuals differ markedly with respect to
their vitamin A status, their susceptibility to
carcinogenic agents could be markedly affected.
There is evidence ofthis relationship in animal
studies, and there are also some reasonably good
new epidemiologic studies that indicate an effect
aswell. Inepidemiologic studies wereally have to
take a look not only at characterizing the exter-
nal exposures to stressor agents, but also at in-
herent biological factors, be they developmental,
genetic, nutritional, orpre-existing disease condi-
tions, which could play a role in the sensitivity of
the individual to outcomes we are measuring.
DR. CANTOR: Over the past several years, the
role that vitamin A and other nutrients may play
inmodifying the risk ofcancer has received much
attention. The hypothesis of the possible influ-
ence of vitamin A on the transformation of epi-
thelial tissue was in its infancy in 1977 when the
bladder cancer study was designed, and it re-
mains a matter ofconsiderable controversy.
I don't think that ignoring possible effects of
vitamin A in our study will affect its findings in a
significant way, even ifthe hypothesis is valid. If
we observe consistent relationships with water
exposure variables among smokers, nonsmokers,
males, females, the occupationally exposed, and
those not so exposed; ifwe see dose-response rela-
tionships; if we are able to say something about
the latent period; then I think we can convinc-
ingly argue that our findings did not result from
confounding by dietary factors.
DR. EDWARD P. RADFORD (Univ. ofPittsburgh):
I think we have to bear in mind that in a sympo-
sium like this the convinced are talking to the
convinced. The fact of the matter is that in the
world at large the situation is very different from
that expressed by the comments today. For exam-
ple, if we have a few good epidemiologic studies
and some toxicology to back it up, then all we
have to worry about is economics in order to be
able to regulate. In my opinion the economics
have never been adequately evaluated. I haven't
seen a cost-benefit analysis yet that I think is
believable by professional economists, let alone
by epidemiologists like us. Usually the outcome
is: Let's keep going the way we are because it is
going to cost too much to do anything.
We also have vigorous attacks against the De-
laney clause, which relates essentially to animal
data. Thus we may be moving in the direction of
large global epidemiologic studies in order to test
hypotheses already made. This possibility is leav-
ing a vacuum for new hypotheses. There are a
great many studies that need to be done. I would
like to echo what Dr. Enterline just said, that
there are enormous opportunities for studies, not
necessarily expensive, that can be done relatively
quickly by looking at targets ofopportunity. Ifwe
are too concerned about what epidemiology is
doingornotdoing intheregulatoryprocess, these
opportunities are going to be lost.
DR. COTRUVO: What you say is correct on the
issue of having sufficient studies from which to
make these regulatory decisions; and the fact
that there are pressures on the other side not to
regulate. Ifthere is acredible epidemiologic study
that permits the conclusion that there is real risk
involved, then Ithinksociety getsmobilized, deci-
sions are made and reductions of exposure are
incurred. History shows that. So I don't think
that is the problem. The problem arises when
there is a lot ofuncertainty, both on the scientificDISCUSSION: SESSION IV
side and on the economic side. I agree with you
that economics isn't necessarily any more precise
than biomedical science.
There are shifts in philosophy that occur with
time. Maybe five years ago the philosophy was
very strongly in aprotective direction, and maybe
now it is a little less so in some quarters. The
point is, if the case is good, it will carry. I wish
there were a lot oftargets ofopportunity that will
answer a lot of these questions at low cost. I
wonder why they didn't occur in the last five
years and why will they begin to appear now.
The problems are great and complicated, and
there are not easy answers. But I repeat, it is still
ultimately economics that controls regulatory de-
cisions, whether there are precise analytical pre-
dictors ofeffects or not. The cost-benefit equation
is tilted one way or another based on the strength
ofthe science to induce the change.
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